LKLakshmanan Krishnamurti

Lakshmanan Krishnamurti

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lakshmanan Krishnamurti has a total of 310 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Reduced-Intensity Haploidentical Bone Marrow Transplantation in Children with Severe Sickle Cell Disease: BMT CTN 1507

    by Mark C. Walters, Adetola A. Kassim, Mary Eapen, Lori C Jordan, Sumit Pruthi, Elton B Greene, Madoc Smith, Jordan Milner, Robert S Nickel, Catherine M. Bollard, et al.

    This is a multi-center, single-arm, phase-II, trial (NCT03263559) of haploidentical bone marrow transplant (BMT) for children with severe sickle cell disease (SCD). Eligible participants were children 5.00 - 14.99 years of age with stroke (silent or overt), abnormal transcranial Doppler cerebral arterial velocity > 200 cm/sec with intracranial vasculopathy, severe acute chest syndrome (ACS) or recurrent vaso-occlusive pain. The primary outcome was 2-year event-free survival (EFS; alive and disease-free). The transplant regimen included hydroxyurea 30mg/kg/day (Day-60 to Day-10), followed by thymoglobulin, thiotepa, fludarabine, cyclophosphamide, and total body irradiation (200 cGy). Graft-versus-host disease (GVHD) prophylaxis included post-transplant cyclophosphamide (PTCy), sirolimus and mycophenolate mofetil. Forty-one participants were enrolled from 18 sites and 95% (39/41) proceeded to BMT. The median age at enrollment was 12.5 years; 98% (38/39) had hemoglobin SS disease, and 82.1% (32/39) had donors mismatched at 4 HLA-loci. The most common indication for BMT was a qualifying neurological event in 69% (27/39), including 15 with overt stroke. Nine participants had recurrent vaso-occlusive pain and 5, severe ACS. The 2-year EFS and overall survival were 79.3% (95% CI: 62.8%, 89.1) and 94.5% (95% CI: 79.7%, 98.6%), respectively. FEV1% predicted increased from 79.5 to 95.7 at 2 years (p=0.014), and eGFR declined from 174 to 127 mL/min/1.73m2 (p<0.001), indicating resolved hyperfiltration. No new or progressive cerebral infacts were detected by serial brain MRI per central adjudication (n=22). While graft failure and GVHD negatively impacted EFS, reduced-intensity haploidentical BMT with PTCy is a promising therapy for children who lack a matched sibling donor.

  • Addressing the slow uptake of gene therapy for sickle cell disease: a lack of interest, a high cost, or a more complex issue?

    by Lakshmanan Krishnamurti, Aishwarya Aiyer, Karthik Rayapureddi

    1. Sickle cell disease (SCD) is a recessively inherited hemoglobinopathy associated with considerable morbidity [1], healthcare utilization, impaired health-related quality of life (HRQL) [1–5], an...

  • Open Access

    Haploidentical transplant, gene therapy, and standard care in sickle cell disease: a cost-effectiveness analysis

    by Karthik Chetlapalli, Satoko Ito, Ding Quan Ng, Manraj Singh Sra, Daniel Wang, Harlan Krumholz, Lakshmanan Krishnamurti, Ankur Pandya, George Goshua

    Non-myeloablative-related haploidentical allogeneic stem cell transplantation (NMAC-HID allo-HSCT) emerged as an additional treatment for achieving durable remission in SCD, a prevalent blood disorder characterized by painful vaso-occlusive crises and chronic anemia. The standard-of-care (SOC) for SCD includes hydroxyurea, pain management, and blood transfusion, but patients with SCD still lose several decades of life expectancy. Gene therapy (GT) for SCD is the other treatment for lifelong disease amelioration in SCD, with accessibility limited by cost and manufacturing capacity in the US and globally. Two recent prospective studies evaluating NMAC-HID allo-HSCT validated haploidentical allotransplantation as an efficacious and accessible treatment option in the era of gene therapy. Given ongoing price negotiation across jurisdictions for GT implementation and the absence of cost-effectiveness data comparing NMAC-HID allo-HSCT versus GT, we conducted a cost-effectiveness analysis of NMAC-HID allo-HST versus GT versus SOC for adults and children living with SCD. The primary outcomes were the incremental cost-effectiveness ratio and the net monetary benefits (NMBs) across these three strategies. The secondary outcome was the maximum cost-effective threshold price for GT compared to NMAC-HID allo-HSCT. Treatment with SOC, NMAC-HID allo-HSCT, and GT accrued 14.3, 20.1, and 22.1 QALYs at costs of $1.22 million, $1.15 million and $2.75 million respectively. NMAC-HID allo-HSCT was the cost-effective strategy versus GT in 100% of 10,000 Monte Carlo iterations across the base-case and all scenario analyses. The maximum cost-effective thresholds for GT vs SOC were $1.4 million in the United States and $4,200-$22,000 across India, Nigeria, and Tanzania, depending on willingness-to-pay.


  • Risk Factors for the Development of Avascular Necrosis Following Hematopoietic Cell Transplantation for Sickle Cell Disease

    by Rohaum Hamidi, Vineetha Reddy Nallagatla, Jingchen Liang, Yanhong Deng, Aron Flagg, Niketa C. Shah, Daniel Prior, Lakshmanan Krishnamurti

  • Open Access

    Informed shared decision-making or rigid eligibility and exclusion criteria for gene therapy for sickle cell disease?

    by Lakshmanan Krishnamurti, Ayobami Olafimihan, Lewis L. Hsu

    Hematopoietic cell transplant (HCT) for sickle cell disease from human leukocyte antigen (HLA)-identical sibling and alternate donors is associated with excellent outcomes. HCT was implemented under restrictive eligibility and exclusion criteria because mortality was >10% in the early experience. These restrictive criteria were carried over to contemporary HCT and gene therapy (GT) clinical trials. Additionally, patients with chronic pain, stroke, psychiatric disorders, or adherence issues were excluded from GT trials. The United States Food and Drug Administration qualification of GT broadly identifies recurrent vaso-occlusive episodes (VOE) as the indication and stipulates no exclusion criteria, thus raising the question of which criteria to use in clinical GT. Excellent overall and event-free survival, improvement in health-related quality of life, amelioration of VOE, and stabilization of cerebral vasculopathy following HLA-identical sibling donor HCT and GT justify broad application of GT in patients with a history of severe VOE, with shared decision-making guided by patient preferences while acknowledging gaps in evidence.


  • Open Access

    A road map for uniform, comprehensive long-term follow-up after curative therapy for sickle cell disease

    by Shalini Shenoy, Julie Kanter, Adetola Kassim, Courtney Fitzhugh, Elizabeth Stenger, Monica Bhatia, Lydia Pecker, Lakshmanan Krishnamurti, Allison A. King

    An increasing number of allogeneic transplant and autologous gene modification transplant therapies seek to eradicate sickle hemoglobin and the consequent hemolysis, vasculopathy, functional compromise, morbidity, and mortality. Because these modalities are used in parallel, it is important to be able to define the spectrum and stability of correction, long-term effects, and the pros and cons of each modality. A comparison between interventions that will be sought by providers and patients undergoing intervention requires uniform assessments that evaluate disease- and intervention-related effects for informed decision-making. This expert summary outlines a pathway to functional evaluations with timing recommendations, provides broad management guidelines, and touches upon ongoing research efforts in the field. The road map for long-term follow-up can help clinicians and researchers choose assessments and time them in comparable fashion between the various transformative therapy efforts.


  • Open Access

    Comparison of Regimens Used for Allogeneic Matched Related Donor Hematopoietic Cell Transplantation for Sickle Cell Disease

    by Daniel Prior, Jingchen Liang, Yanhong Deng, Niketa Shah, Aron Flagg, Lakshmanan Krishnamurti


  • Open Access

    Hematopoietic cell transplant compared with standard care in adolescents and young adults with sickle cell disease

    by Mark C. Walters, Mary Eapen, Yiwen Liu, Fuad El Rassi, Edmund K. Waller, John E. Levine, John J. Strouse, Joseph H. Antin, Suhag H. Parikh, Nitya Bakshi, et al.

    Disease-modifying therapies are standard of care (SOC) for sickle cell disease (SCD), but hematopoietic cell transplantation (HCT) has curative potential. We compared outcomes prospectively through 2 years after biologic assignment to a donor or no donor (SOC) arm based on the availability of an HLA-matched sibling or unrelated donor (BMT CTN 1503). A donor search was commenced after eligibility confirmation. The primary end point was a comparison of survival between the treatment arms 2 years after biologic assignment. Power calculations required 60 participants in the donor arm and 140 in the no donor arm to determine if early transplant-related mortality might be balanced by disease-related mortality over a longer period of follow-up. Secondary objectives were a comparison of the changes in SCD-related events, functional outcomes, and organ function. The data were analyzed according to the intent-to-treat principle. A total of 113 participants were enrolled with 28 in the donor arm and 85 in the no donor arm. The 2-year probabilities of survival were 89% and 93%, in the donor vs no donor arms. Vaso-occlusive pain (VOC) was less frequent in the donor arm in the second year after biologic assignment (P < .001). Based on PROMIS-57 surveys, there was a decrease in fatigue (P = .003) and an increase in the ability to participate in social roles and activities (P = .003) in the donor arm 2 years after biologic assignment. Differences in other secondary outcomes did not reach statistical significance. Barriers to accrual prevented an objective comparison of survival. Assignment to the donor arm led to improvements in VOC, fatigue, and social function. This trial was registered at www.clinicaltrials.gov as #NCT02766465.


  • Open Access

    Clinical phenotype of high-impact chronic pain in sickle cell disease at consultation for hematopoietic cell transplant

    by Serena Huang, Scott Gillespie, Eric Chou, Katie Liu, Ashna Jagtiani, Lakshmanan Krishnamurti, Nitya Bakshi

    Introduction/Objective: Lack of a well-characterized phenotype of High-Impact Chronic pain (HICP), that is, chronic pain (CP) with substantial restriction of participation in work, social, or self-care activities remains a critical gap in identifying individuals with CP and SCD at-risk for poor pain outcomes. Methods: Retrospective study using the Electronic Health Record (EHR) at a large academic children’s hospital. Results: We report the clinical phenotype of 46 children with SCD diagnosed with HICP at time of consultation for Hematopoietic Cell Transplant (HCT). The mean age was 14.5 years (SD 3.9), 50% (n = 23) were female, 84.8% (n = 39) had HbSS genotype or similar, 30.4% (n = 14) had avascular necrosis, 84.8% (n = 39) were prescribed at least one disease modifying medication, and 41.3% (n = 19) were prescribed adjuvant analgesics. The cohort experienced a median of 6 (IQR 2, 9) and 8.50 (IQR 4.25, 15) episodes of healthcare utilization (HCU) for pain in 12 months and 24 months prior to the HCT consult, respectively, but about one-third did not experience frequent HCU (three or more episodes/year) for pain. In the 10 years leading up to the HCT consult, the incidence of HCU for pain year-over-year increased on an average by 15%. Clinical correlates of HICP from the EHR like prescription of adjuvant analgesics, cumulative doses of prescribed opioids, and diagnosis codes for CP were more likely to identify those who experienced frequent HCU for pain. Conclusion: HICP in SCD is associated with substantial morbidity. This study underscores the importance of screening for HICP in SCD.